The oral azacitidine/cedazuridine combination was compared with subcutaneous azacitidine in the phase 3 portion of the AZTOUND trial.
|Videos|February 20, 2019
A 75-Year-Old Man With Right-Sided mCRC
A 75-Year-Old Man With Right-Sided mCRC
Advertisement
Case: A 75-Year-Old ManWithRight-Sided mCRC
Initial presentation
- A 75-year-old Caucasian man presented to his PCP with rectal bleeding, fatigue, weight loss, and constipation
Clinical workup
- Colonoscopy: fungating mass in the ascending colon
- Biopsy: invasive, poorly differentiated adenocarcinoma
- Imaging: CT scan of the chest/abdomen/pelvis showed multiple small liver lesions including a 3-cm mass in right lobe
- Molecular testing on tissue biopsy:
- KRAS, RAS, andBRAFWT
- Microsatellite-stable
- ECOG PS 1
Treatment
- Patient underwent a diverting colostomy without complication
- He was started on FOLFOX and bevacizumab
- Follow up imaging at 3, 6, and 9 months showed a partial response
- He was continued on bevacizumab and underwent capecitabine maintenance
- Imaging at 12 months showed 2 new liver lesions (1.2 cm and 3.4 cm)
Advertisement
Related to this article
Adding zabilugene almadenorepvec to standard gemcitabine/nab-paclitaxel extends survival and response in newly diagnosed metastatic pancreatic cancer, with manageable safety signals.
Late 2026 FDA oncology rulings may reshape care—from CSF-1R and ALK drugs to oral SERDs and BCMA CAR T breakthroughs.
Resubmitted FDA filing advances off-the-shelf EBV-specific T-cell therapy tab-cel for relapsed EBV+ PTLD after transplant, with longer follow-up.
Resection with cesium-131 tile-based radiation therapy prolonged time to surgical bed recurrence vs resection with stereotactic radiation in the phase 3 ROADS trial.
Degevma was approved for skeletal-related events in adults with bone metastases, giant cell tumor of bone, and the treatment of hypercalcemia of malignancy.
FDA fast-tracks plinabulin plus docetaxel for post-immunotherapy non-squamous NSCLC, as DUBLIN-4 phase 3 targets survival gains.
September brought accelerated approvals in ESR1-mutant breast cancer and HER2-mutant non–small cell lung cancer, a Galleri panel vote, and a withdrawn I-DXd application.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Plinabulin Receives FDA Fast Track Designation in Post-ICI NSCLC
2
Denosumab Biosimilar Approved For Existing Oncology Indications
3
FDA Oncology Recap: Approvals, Designations, and Decisions in September 2026
4
Tile-Based Radiation Improves Local Control in Resected Brain Metastases
5